Cancer Market Research Reports & Industry Analysis

... , were unveiled (ViewPoints: Investors respond in kind to impressive data for Bristol-Myers Squibb NSCLC immunotherapy). Checkmate-063 recruited 117 patients, each ... , noting that a 21 percent rate (or 18 percent for squamous patients) cited by Bristol-Myers Squibb stemmed from a database comprising only Medicare patients aged ...

... Non Hodgkin Lymphoma therapeutics. “Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight: Global Non Hodgkin Lymphoma Market Overview Mechanism of Non Hodgkin Lymphoma Therapeutics Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company Global Non Hodgkin Lymphoma Pipeline ...

... Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country Cancer Monoclonal Antibodies in Pipeline: 605 Majority Cancer Monoclonal Antibodies Preclinical Phase: 258 Marketed Cancer Monoclonal Antibodies: 34 Cancer Monoclonal Antibodies ...

... Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight: Classification & Mechanism of Kinase Inhibitors Cancer Kinase Inhibitors Therapy Market Overview Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country Marketed Cancer Kinase Inhibitors Therapy ...

... Breast Cancer Vaccine Clinical Trial Insight” Report Highlight: Global Breast Cancer Vaccine Market Overview Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines Detailed Clinical Insight on Breast Cancer Vaccine Pipeline ...

... Yervoy (ipilimumab) and, if BRAF V600-mutation positive, a BRAF inhibitor (see also Physician Views Poll Results – Oncologists suggest Mekinist/Tafinlar combination will ... approval – the PD-1/PD-L1 inhibitors are expected to spearhead evolution of a multi-billion dollar market over the next decade – this Physician Views poll contains a second ...

... Cancer Vaccines Delivery Cancer Vaccines: Mechanism & Innovations Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country Global Cancer Vaccine Clinical Pipeline: 289 Vaccines Marketed Cancer Vaccines: 12 Vaccines Regulatory Framework for Cancer Vaccines Development & Marketing ...

... 4/6 inhibitor class. Expectations for palbociclib were flying high in 2012 when Pfizer reported preliminary results from the Phase II PALOMA-1 trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2 ...

... trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional ... therapy, both conventional and peptide based cancer therapeutics are used for the treatment. “Global Peptide Cancer Therapeutics Market & Pipeline Insight ...

... growth. According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US$ 91 Billion in 2013 ... future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the ...

... maintaining front line, product level access and education. In Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies, FirstWord ... marketed and four pipeline products Examination of physicians’ current usage of Medical Affairs teams services Key findings regarding the most and ...

... is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, ...

... is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the European Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, ...

... and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the French Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. French Market Overview Five-year test volume and sales ...

... and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the German Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. German Market Overview Five-year test volume and sales ...

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Italian Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Italian Market Overview Five-year test volume and sales ...

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Japanese Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Japanese Market Overview Five-year test volume and sales ...

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Spanish Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Spanish Market Overview Five-year test volume and sales ...

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Spanish Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Spanish Market Overview Five-year test volume and sales ...

... be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, ... growing demand for malignancy assays and the rapid market expansion. US Market Overview Five-year test volume and sales projections ...

... use. “Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights: Cancer Immunotherapy Market Overview Cancer Immunotherapy Market Dynamics Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country Cancer Vaccine Clinical ...

... experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging ...

... growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing ... held a market share of ~% and recorded sales of USD ~ million. The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with ...

... tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ... of over 500 companies, universities and research centers developing new tumor markers and detection technologies. Competitive Assessments Extensive strategic assessments ...

... are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies ... improve quality of life. “Cancer Cytokines Therapy Pipeline Analysis” Report Highlights: Cancer Cytokines Therapy Market Overview Marketed Drug Profiles & Patent ...

... the spread of cancer. “Cancer Cell Therapy Market & Pipeline Insight” Report Highlights & Findings: Cancer Cell Therapy Market Overview Cancer Cell Therapy Market Dynamics Clinical Pipeline by Phase, country & Target Indications Cancer Cell Therapy Drugs in Pipeline: 82 Highest Number of Drugs in Preclinical ...

The Personalized Medicine in Oncology Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the world’s leading healthcare companies in oncology sector. All the deals have been tracked year wise. All the deals ...

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how physicians value the role that medical affairs personnel play. Specifically we asked US and EU5-based oncologists: How important they view ...

... . DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, ... during the nextfive years. The report examines trends in the French cancer diagnostics markets, reviews current and emerging assays; analyzes ...

... . DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, ... during the nextfive years. The report examines trends in the German cancer diagnostics markets, reviews current and emerging assays; analyzes ...

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the Italian ...

Complete report $8,800. DataPack (test volumes, sales forecasts, supplier shares) $5,700. New Frontiers in the Japanese Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the ...

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the Spanish ...

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the UK Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the UK cancer ...

Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400. New Frontiers in the U.S. Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the U.S. cancer ...

... . DataPack (test volumes, sales forecasts, supplier shares) $21,100. New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape is Venture ... specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer ...

Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800. New Frontiers in the European Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the ...

... early access to a new cancer product, but a number of developers have also highlighted notable benefits derived from the process. To assess the view of expanded access programmes from the position of the physician community, FirstWord is polling oncologists based in the ...

... have their own particular views on how this resource can be used to improve the treatment of patients in the future? Are they aware of the ... physician perceptive towards real-world data, FirstWord polled 192 oncologists based in the US and EU5. Specifically we asked them How aware they are ...

... are as follows 1. United Kingdom 2. France 3. Germany 4. Italy 5. Spain 6. Sweden 7. Switzerland 8. Norway 9. Netherlands 10. United States 11. Canada 12. Japan 13. Korea 14. Singapore 15. Malaysia 16. Australia 17. India 18. China 19. Thailand 20. Indonesia Data Sources This report is built using data ...

... KOL analysis of NSCLC treatments, development and competition, KOL Insight: Non-small cell lung cancer is an essential tool for keeping abreast of events that will shape ... Developments in the treatment of NSCLC are progressing rapidly. In KOL Insight: Non-small cell lung cancer, you will: Gain an invaluable overview into the most dynamic ...

... of Oncology Therapeutics in Gene Therapy Current Applications of Gene Therapy to Cancer Treatment Favorable Parameters for Cancer Gene Therapy Issued Involved with Application of Gene Therapy in Cancer Patients Regulatory Scenario for Gene Therapy Market Cancer Gene Therapy Drug Clinical ...

... and the exponential decline in cost of whole genome sequencing. Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed ... in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for ...

This new report from Venture Planning Group provides strategic assessments of major cancer diagnostic product suppliers and emerging market entrants. The report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product ...

... opinion This new KOL Insight report Breast Cancer –new targeted therapies transform treatment provides everyone interested in this dynamic cancer sector with a complete understanding of the targeted products ... and weaknesses of currently available targeted therapies for breast cancer Assess how prescribing trends will change with launch of new products Identify promising late-stage ...

... strategic analyses of leading current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 104 pages and 3 tables

... 533 pages, 43 tables, and presents a comprehensive analysis of the French hospital tumor marker testing market, including: Major issues pertaining to the ... , oral, skin and others. Test volume and sales forecasts for 40 tumor markers performed in French hospitals. Current instrumentation technologies and ...

... 530 pages, 40 tables, and presents a comprehensive analysis of the German hospital tumor marker testing market, including: Major issues pertaining to the ... , oral, skin and others. Test volume and sales forecasts for 40 tumor markers performed in German hospitals. Current instrumentation technologies and ...

... 525 pages, 38 tables, and presents a comprehensive analysis of the Italian hospital tumor marker testing market, including: Major issues pertaining to the ... , oral, skin and others. Test volume and sales forecasts for 40 tumor markers performed in Italian hospitals. Current instrumentation technologies and ...

... 537 pages, 42 tables, and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including: Major issues pertaining to the ... , oral, skin and others. Test volume and sales forecasts for 40 tumor markers performed in Japanese hospitals. Current instrumentation technologies and ...